Initiatives to speed new drug development and regulatory review: The impact of FDA-sponsor conferences.

被引：0
|
作者：
DiMasi, JA [1 ]
Manocchia, M [1 ]
Lasagna, L [1 ]
机构：
[1] TUFTS UNIV, TUFTS CTR STUDY DRUG DEV, BOSTON, MA 02111 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1996年 / 59卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：PII13 / PII13
页数：1
相关论文
共 17 条
  • [1] Initiatives to Speed New Drug Development and Regulatory Review: The Impact of FDA-Sponsor Conferences
    Joseph A. DiMasi
    Michael Manocchia
    [J]. Drug information journal : DIJ / Drug Information Association, 1997, 31 (3): : 771 - 788
  • [2] FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes
    Kesselheim, A. S.
    Darrow, J. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (01) : 29 - 36
  • [3] Understanding FDA Regulatory Requirements for Investigational New Drug Applications for Sponsor-Investigators
    Holbein, M. E. Blair
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (06) : 688 - 694
  • [4] New FDA recommendations to speed drug development
    Shalev M.
    [J]. Lab Animal, 2006, 35 (3) : 13 - 13
  • [5] IMPACT OF FDA EXPEDITED REVIEW PROGRAMS ON NEW DRUG APPROVAL TIME
    Ronnebaum, S.
    Smith, D.
    Andrawes, M.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S7 - S7
  • [6] Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway
    Salminen, William F.
    Wiles, Marc E.
    Stevens, Ruth E.
    [J]. DRUG DISCOVERY TODAY, 2019, 24 (01) : 46 - 56
  • [7] Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science
    Rodney Rouse
    Naomi Kruhlak
    James Weaver
    Keith Burkhart
    Vikram Patel
    David G. Strauss
    [J]. Therapeutic Innovation & Regulatory Science, 2018, 52 : 244 - 255
  • [8] Translating New Science Into the Drug Review Process: The US FDA's Division of Applied Regulatory Science
    Rouse, Rodney
    Kruhlak, Naomi
    Weaver, James
    Burkhart, Keith
    Patel, Vikram
    Strauss, David G.
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (02) : 244 - 255
  • [9] Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice
    Huang, S-M
    Temple, R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (03) : 287 - 294
  • [10] A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
    M. Mitroiu
    K. Oude Rengerink
    S. Teerenstra
    F. Pétavy
    K. C. B. Roes
    [J]. Trials, 21
12